Ligand Pharmaceuticals Company Profile (NASDAQ:LGND)

Analyst Ratings

Consensus Ratings for Ligand Pharmaceuticals (NASDAQ:LGND) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $145.75 (8.06% upside)

Analysts' Ratings History for Ligand Pharmaceuticals (NASDAQ:LGND)
Show:
DateFirmActionRatingPrice TargetActions
7/19/2016Roth CapitalReiterated RatingBuy$147.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/13/2016StephensInitiated CoverageOverweight$150.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016SidotiInitiated CoverageBuy$140.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2016HC WainwrightInitiated CoverageBuy$146.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/19/2015Cantor FitzgeraldBoost Price TargetHold$86.00 -> $93.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2015Deutsche Bank AGDowngradeBuy -> Hold$94.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2015Craig HallumReiterated RatingBuy$90.00 -> $105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015CRT CapitalInitiated CoverageBuy$102.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/8/2014ING GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Ligand Pharmaceuticals (NASDAQ:LGND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016Q216$0.40$18.12 millionN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2016Q116$0.67$0.97$26.45 million$29.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2016Q415$0.65$0.66$24.71 million$21.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315$0.42$0.56$17.80 million$17.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215$0.40$1.81$17.00 million$18.42 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115$0.27$0.33$13.50 million$14.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/9/2015Q414$0.60$0.60$23.88 million$23.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2014Q314$0.31$0.36$14.60 million$15.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2014Q214$0.14$0.24$9.73 million$10.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014Q114$0.25$0.35$13.63 million$16.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2014Q413$0.19$0.35$13.72 million$14.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2013Q213$0.07$0.12$10.81 million$13.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013$0.06$0.07$9.48 million$9.58 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2013Q1 2013$0.09$0.16$10.00 million$11.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/13/2013Q4 2012$0.19$12.90 million$13.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2012Q312$0.04($0.01)$8.40 million$6.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ligand Pharmaceuticals (NASDAQ:LGND)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.44$0.46$0.45
Q2 20161$0.54$0.54$0.54
Q3 20162$0.62$0.63$0.63
Q4 20162$1.08$1.16$1.12
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ligand Pharmaceuticals (NASDAQ:LGND)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ligand Pharmaceuticals (NASDAQ:LGND)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/1/2016John W KozarichDirectorSell1,000$121.40$121,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016John W KozarichDirectorSell1,000$117.42$117,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2016Melanie J HermanDirectorSell334$120.50$40,247.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2016Jason AryehDirectorSell25,000$119.20$2,980,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016John W KozarichDirectorSell1,000$121.57$121,570.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2016John W KozarichDirectorSell5,000$115.00$575,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Matthew W FoehrCOOSell6,400$96.70$618,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/8/2016Jason AryehDirectorSell6,129$101.18$620,132.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2016John L HigginsCEOSell10,833$102.47$1,110,057.51View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2016John W. KozarichDirectorSell1,666$94.94$158,170.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Melanie J. HermanDirectorSell7,719$101.00$779,619.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015David M KnottDirectorSell4,000$95.98$383,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015David M KnottDirectorSell49,800$96.26$4,793,748.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2015Charles S BerkmanVPSell14,067$99.14$1,394,602.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2015Matthew W FoehrCOOSell12,500$100.97$1,262,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2015Matthew W FoehrCOOSell23,046$96.45$2,222,786.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Melanie J HermanCFOSell4,125$93.50$385,687.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2015John L HigginsCEOSell10,000$92.88$928,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2015Jason AryehDirectorSell1,640$92.68$151,995.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2015Jason AryehDirectorSell9,240$87.34$807,021.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2015Nishan M DesilvaCFOSell68,363$83.91$5,736,339.33View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Sunil PatelDirectorSell4,591$74.42$341,662.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2015Nishan M DesilvaVPSell2,300$56.34$129,582.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2014John W KozarichDirectorBuy2,000$45.68$91,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/9/2014Jason AryehDirectorBuy11,000$42.99$472,890.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014John L HigginsCEOBuy1,000$54.97$54,970.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2014Melanie J HermanDirectorSell1,100$69.68$76,648.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2014Charles S BerkmanVPSell7,166$66.90$479,405.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2014Bvf Partners P/IlInsiderSell78,226$70.09$5,482,860.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2014Todd DavisDirectorSell7,500$79.57$596,775.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2014John LamattinaDirectorSell5,000$78.83$394,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2014Bvf Partners P/Ilmajor shareholderSell422,900$73.81$31,214,249.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014David KnottDirectorSell41,900$75.71$3,172,249.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2014Jason AryehDirectorSell40,320$76.44$3,082,060.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2014Matthew FoehrCOOSell22,500$79.54$1,789,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2013Matthew FoehrCOOSell6,000$53.40$320,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2013John SharpCFOSell6,000$56.08$336,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/18/2013John L HigginsCEOSell10,000$55.00$550,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2013Bvf Partners P/Ilmajor shareholderSell359,023$44.50$15,976,523.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2013David KnottDirectorSell160,000$46.78$7,484,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/30/2013Charles BerkmanVPSell28,323$47.54$1,346,475.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013Charles BerkmanVPSell14,583$42.63$621,673.29View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013John HigginsCEOSell10,000$42.85$428,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013John SharpCFOSell7,500$42.75$320,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/28/2013Matthew W FoehrCOOBuy1,059$17.36$18,384.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2013Charles S BerkmanVPSell4,000$26.66$106,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2013Bvf Partners L P/IlMajor ShareholderBuy39,600$19.78$783,288.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/14/2012Bvf Partners L P/IlMajor ShareholderBuy5,386$18.63$100,341.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2012Bvf Partners L P/IlMajor ShareholderBuy50,100$17.94$898,794.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2012John L HigginsCEOBuy2,000$18.03$36,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/31/2012Bvf Partners L P/IlMajor ShareholderBuy16,591$15.19$252,017.29View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2012David M KnottDirectorBuy2,743$16.36$44,875.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ligand Pharmaceuticals (NASDAQ:LGND)
DateHeadline
07/29/16 05:05 PMLigand Pharmaceuticals : Announces Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals
07/29/16 05:05 PMLigand Pharma (LGND) Enters LTP Tech Licensing Agreement
07/29/16 07:55 AMLigand Pharma (LGND) Enters LTP Tech Licensing Agreement - StreetInsider.com
07/29/16 07:50 AMLIGAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events -
07/29/16 07:30 AMLigand Announces Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals - [Business Wire] - SAN DIEGO--(BUSINESSWIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - News) announces the signing of a license agreement for three programs utilizing Ligand’s LTP (Liver Targeting Prodrug) technology with Nucorion Pharmaceuticals, Inc., a venture-funded biotechnology company focused on developing anti-cancer and anti-viral agents initially directed to China. Ligand’s LTP technology is a novel prodrug technology platform designed to selectively deliver a range of active pharmaceutical agents to the liver.
07/22/16 07:54 AMLigand Pharmaceuticals Reaches Analyst Target Price - Nasdaq
07/22/16 07:54 AMLigand Pharmaceuticals Inc. Stock Is Rising Now - Consumer Eagle
07/21/16 11:05 AMLigand Pharmaceuticals Reaches Analyst Target Price
07/20/16 09:28 PMLigand Pharmaceuticals Incorporated (LGND) Jumps 5.52% on July 20 - Equities.com
07/20/16 09:28 PMLigand Pharmaceuticals Inc. Hit 52-Week High - Press Telegraph
07/18/16 05:07 PMWhat Will Happen to Ligand Pharmaceuticals Inc. Next? The Stock Formed a Several Months Double Top Pattern - Consumer Eagle
07/18/16 10:07 AMHow Much Potential Does Promacta Hold? -
07/18/16 08:08 AMLigand Pharmaceuticals’s Portfolio Pyramid as Its Valuation Catalyst -
07/15/16 09:03 AMLigand Pharmaceuticals Inc (NASDAQ:LGND): Continue to Grow - Street Report
07/14/16 08:32 AMTurner Investments LP Increased Ligand Pharmaceuticals INC (NASDAQ:LGND) by $4.39 Million as Shares Rose - Consumer Eagle
07/14/16 08:00 AMLigand to Report Second Quarter Results on August 4th - [Business Wire] - Ligand Pharmaceuticals Incorporated announced today plans to report second quarter 2016 financial results on August 4, 2016. Ligand’s CEO John Higgins, President and COO Matt Foehr and CFO Matt Korenberg will host the conference call.
07/12/16 05:12 PMHere's Why SAGE Therapeutics Inc. Is Surging Today - Motley Fool
07/12/16 03:07 PMSage Therapeutics' Post-Partum Depression Drug Scores; Stock Up -
07/12/16 11:31 AMHere's Why SAGE Therapeutics Inc. Is Surging Today -
07/11/16 09:38 AMLigand Pharmaceuticals (NASDAQ:LGND) Sellers Covered 0.86% of Their Shorts - Press Telegraph
07/10/16 04:28 PMLigand Pharma (LGND) Enters OmniAb Licensing Agreement with Gilead (GILD)
07/10/16 04:28 PMLigand Enters into OmniAb® Platform License Agreement with Gilead Sciences
07/08/16 05:02 PMLigand Pharma (LGND) Enters OmniAb Licensing Agreement with Gilead (GILD) - StreetInsider.com
07/08/16 10:54 AMLigand Reaches OmniAb Platform License Agreement with Gilead - Ligand Pharmaceuticals Inc. (NASDAQ: LGND) disclosed that it reached a worldwide license agreement with Gilead Sciences, Inc. (NASDAQ: GILD). According to the company, Gilead would be able to use the OmniRat, OmniMouse and OmniFlic platforms under the license agreement to discover fully human mono- and bispecific antibodies to be developed for the ...Full story available on Benzinga.com
07/08/16 07:51 AMTurner Investments LP Decreased Stake in Hubspot INC (NYSE:HUBS) by $4.13 Million as Shares Declined - Press Telegraph
07/07/16 07:51 AMLigand Pharmaceuticals (NASDAQ:LGND) Shorts Decreased by 0.86% After Short Covering - Engelwood Daily
07/04/16 04:27 PMLigand Pharmaceuticals Inc (NASDAQ:LGND) Institutional Investors Sentiment Up in 2016 Q1 - Engelwood Daily
07/01/16 04:21 PMLigand Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LGND) : July 1, 2016 -
07/01/16 07:45 AMLigand Pharmaceuticals (NASDAQ:LGND) Shorted Shares Decreased By 0.86% - Press Telegraph
06/30/16 03:20 PM4:20 pm Ligand Pharma receives $4 mln from expansion of two OmniAb license agreements; including the payments co anticipates total Q2 revs of ~$19 mln vs. $18.13 mln Capital IQ Consensus -
06/30/16 03:02 PMLigand Receives $4 Million from Expansion of Two OmniAb® License Agreements - [Business Wire] - SAN DIEGO--(BUSINESSWIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - News) announces that two recent events relating to its OmniAb platform generated $4 million in combined payments due to Ligand. In exercising its option, an OmniAb licensee broadened its access to the OmniAb platform by adding OmniFlic®, a transgenic rat technology with a fixed light chain used to generate bispecific antibodies. The option exercise triggered a payment to Ligand.
06/27/16 09:17 AMLigand Pharmaceuticals (NASDAQ:LGND) Shorts Decreased by 0.86% After Short Covering - Press Telegraph
06/21/16 09:26 AMGurus Invest in Top Biotechnology Stocks - GuruFocus.com
06/07/16 05:07 PMNovartis AG (NYSE:NVS), Eisai Co., Ltd (OTCMKTS:ESALY) To Cooperate In Cancer Drugs Marketing In The U.S. - Market Exclusive
06/07/16 04:41 PMETF’s with exposure to Ligand Pharmaceuticals, Inc. : June 7, 2016 -
06/04/16 04:58 PMState Street Corp Decreased Stake in Lockheed Martin Corp (NYSE:LMT) by $127.86 Million as Shares Rose - CCH Daily News
06/04/16 07:42 AMLigand Pharmaceuticals Inc. (LGND) Director John W. Kozarich Sells 1000 Shares - Let Me Know About This
06/03/16 05:18 PMMacquarie Group LTD Decreased Stake in Edison International (NYSE:EIX) by $44.91 Million as Shares Rose - CCH Daily News
06/02/16 07:19 AMLigand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : June 2, 2016 -
05/31/16 09:06 AMLigand Pharmaceuticals Inc (LGND): David M. Knott of Dorset Management Resigned from the Board - Insider Monkey (blog) - Insider Monkey (blog)Ligand Pharmaceuticals Inc (LGND): David M. Knott of Dorset Management Resigned from the BoardInsider Monkey (blog)David M. Knott's Dorset Managment, recently filed an amended 13D, with the US SEC, reporting David Knott's resignation from the board of the directors of Ligand Pharmaceuticals Inc (NASDAQ:LGND), for reasons that are unconnected to the company.and more »
05/28/16 07:45 PMTurner Investments LP Increased Ligand Pharmaceuticals INC (NASDAQ:LGND) by $4.39 Million as Shares Rose - CCH Daily News - Turner Investments LP Increased Ligand Pharmaceuticals INC (NASDAQ:LGND) by $4.39 Million as Shares RoseCCH Daily NewsTurner Investments Lp increased its stake in Ligand Pharmaceuticals Inc (NASDAQ:LGND) by 205.15% based on its latest 2016Q1 regulatory filing with the SEC. Turner Investments Lp bought 41,030 shares as the company's stock rose 4.51% with the market ...Are Analysts Bullish Ligand Pharmaceuticals Inc. (NASDAQ:LGND) After Last Week?Franklin IndependentLigand Pharmaceuticals Incorporated (NASDAQ:LGND) moved up 0.70%: Rockwell Collins Inc. (NYSE:COL), MAG ...Benchmark MonitorCurrent Price Targets For Ligand Pharmaceuticals Incorporated (LGND)Risers & Fallersall 7 news articles »
05/26/16 09:15 PMIs Best Biotech Stock Buy Now, GILD Or ? You Pick - Here is an alternative set of prospective price range potentials, with indications of how the today's outlook has fared in the marketplace following many prior experiences for Ligand Pharmaceuticals Inc. (NASDAQ:LGND). The same persuasive factors are at ...
05/25/16 03:02 PMLIGAND PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a -
05/20/16 01:44 AMInsider Selling: Ligand Pharmaceuticals Inc. (NASDAQ:LGND)'s Director of Accounting Melanie Herman Sold 334 shares - Wall Street Hints and News - Insider Selling: Ligand Pharmaceuticals Inc. (NASDAQ:LGND)'s Director of Accounting Melanie Herman Sold 334 sharesWall Street Hints and NewsAfter the publishing of a public document filled with Security and Exchange Commission; an important and highly notable insider trade became apparent. The Director of Accounting of Ligand Pharmaceuticals Inc, Melanie Herman; made a huge trade in the ...
05/18/16 12:04 PMLIGAND PHARMACEUTICALS INC Financials -
05/13/16 08:59 PMStocks within Traders Screening: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) , TrovaGene, Inc. (NASDAQ ... - Street Updates - Stocks within Traders Screening: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) , TrovaGene, Inc. (NASDAQ ...Street UpdatesOn 5/12/2016, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ended trading session higher at $116.62 with +0.21%. The company traded a volume of 501.24 thousand shares as comparison to average volume of 417.21 thousand shares. During the ...
05/11/16 09:12 PMLigand Pharmaceuticals To Participate In BOA Merrill Lynch Conference At 2:20 PM - Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages. Please note that once you make your selection, it will apply to all future visits to NASDAQ.com. If ...
05/09/16 02:34 PMETF’s with exposure to Ligand Pharmaceuticals, Inc. : May 9, 2016 -
05/09/16 07:16 AMLIGAND PHARMACEUTICALS INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements and -
05/08/16 11:42 PMEarnings Per Share for Ligand Pharmaceuticals Inc. (LGND) Projected to Decline - B.O.D.Y Confidential - Earnings Per Share for Ligand Pharmaceuticals Inc. (LGND) Projected to DeclineB.O.D.Y ConfidentialWall Street await Ligand Pharmaceuticals Inc. (NASDAQ:LGND) to release earnings on May, 9. Analysts forecast earnings per share of $0.46, up exactly $0.26 or 130.00% from 2014's $0.2 EPS. The expected LGND's profit could reach $9.65M giving the stock ...Ligand Pharmaceuticals (NASDAQ:LGND) Short Interest Decreased By 5.63%Franklin Independentall 3 news articles »

Social

About Ligand Pharmaceuticals

Ligand Pharmaceuticals logoLigand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development. Its partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. It is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: LGND
  • CUSIP: 53220K50
Key Metrics:
  • Previous Close: $134.88
  • 50 Day Moving Average: $123.06
  • 200 Day Moving Average: $111.81
  • P/E Ratio: 11.10
  • P/E Growth: 0.89
  • Market Cap: $2.81B
  • Beta: 1.01
  • Current Year EPS Consensus Estimate: $2.72 EPS
  • Next Year EPS Consensus Estimate: $4.25 EPS
Additional Links:
Ligand Pharmaceuticals (NASDAQ:LGND) Chart for Saturday, July, 30, 2016